

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT2789056

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
MARC MANSOUR	03/06/2014
LISA DIANA MACDONALD	03/06/2014
GENEVIEVE MARY WEIR	03/06/2014
LEELADHAR SAMMATUR	03/06/2014
KENDALL SHARP	03/06/2014
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	IMMUNOVACCINE TECHNOLOGIES INC.
<b>Street Address:</b>	1344 SUMMER STREET
<b>Internal Address:</b>	SUITE 412
<b>City:</b>	HALIFAX - NOVA SCOTIA
<b>State/Country:</b>	CANADA
<b>Postal Code:</b>	B3H 0A8
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	14347928
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(312)655-1501
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	312-655-1500
<b>Email:</b>	pto-chi@huschblackwell.com
<b>Correspondent Name:</b>	HUSCH BLACKWELL LLP
<b>Address Line 1:</b>	120 S RIVERSIDE PLAZA
<b>Address Line 2:</b>	22ND FLOOR
<b>Address Line 4:</b>	CHICAGO, ILLINOIS 60606
<b>ATTORNEY DOCKET NUMBER:</b>	117352
<b>NAME OF SUBMITTER:</b>	GERALD T. SHEKLETON
<b>SIGNATURE:</b>	/Gerald T. Shekleton/
<b>DATE SIGNED:</b>	03/27/2014
<b>Total Attachments: 3</b>	

PATENT

source=117352assignment#page1.tif

source=117352assignment#page2.tif

source=117352assignment#page3.tif

**ASSIGNMENT**

WHEREAS, we, Marc MANSOUR, Lisa Diana MACDONALD, Genevieve Mary WEIR, Leeladhar SAMMATUR and Kendall SHARP, citizens of Canada, residing at, respectively, 17 Alton Drive, Halifax, Nova Scotia, B3N 1L8, Canada; 5385 Duffus Street, Halifax, Nova Scotia, B3K 2L9, Canada; 468 Spring Avenue, Dartmouth, Nova Scotia, B2W 1X8, Canada; 21 Parkland Drive, Apt#317, Halifax, Nova Scotia, Canada; and 6038 Leeds Street, Halifax, Nova Scotia, B3K 2T5, Canada (hereinafter referred to as the "Assignors"), have made certain inventions and discoveries disclosed in International Application Serial No. PCT/CA2012/050705, entitled LIPOSOME COMPOSITIONS COMPRISING AN ADJUVANT THAT ACTIVATES OR INCREASES THE ACTIVITY OF TLR2 AND USES THEREOF filed on October 5, 2012, claiming priority from United States Provisional Application Serial No. 61/544,020 filed on October 6, 2011, (hereinafter referred to as the "Application");

AND WHEREAS, IMMUNOVACCINE TECHNOLOGIES INC., whose full post office address is 1344 Summer Street, Suite 412, Halifax, Nova Scotia, B3H 0A8, Canada (hereinafter referred to as the "Assignee"), is desirous of acquiring the entire right, title, and interest in and to said inventions and discoveries, and in and to the Application inclusive of any and all priority rights derived therefrom for any and all countries in the world, and in and to any and all Letters Patent issuing in any and all countries in the world, to be granted for said inventions and discoveries based on said Application or on patent applications filed in any country claiming priority from said Application;

NOW, THEREFORE, in consideration of the sum of One Dollar (\$1.00), and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, we the Assignors, do hereby sell, assign, transfer, and set over unto the Assignee, its successors and assigns, our entire right, title, and interest in and to the inventions and discoveries disclosed in the Application, and in and to the Application and any continuations or divisions thereof and all priority rights derived therefrom, and in and to any and all patent applications and any continuations or divisions thereof filed in any country claiming priority from the Application, and in and to all Letters Patent which may be granted upon the Application or upon patent applications filed in any and all countries in the world including the United States of America, claiming priority from the Application, and in and to any and all reissues, substitutions, or prolongations thereof; the same to be held and enjoyed by the Assignee for its own use and behoof, and for the use and behoof of its successors and assigns, to the full end of the term or terms for which said Letters Patent, or reissues, substitutions, or prolongations thereof may be granted, as fully and entirely as the same would have been held and enjoyed by us had this assignment and sale not been made;


AND we hereby agree that, upon request, and without further consideration, but at the expense of the Assignee, we will communicate to the Assignee or its representatives or nominees any

facts known to us respecting said inventions and discoveries and testify in any legal proceedings, sign all lawful papers, execute all divisional, continuing, and reissue applications, make all rightful oaths and generally aid the Assignee, its successors, assigns, and nominees to obtain and enforce proper patent protection for said inventions and discoveries in all countries, and we further agree to execute any and all further papers which may be necessary or desirable to vest or perfect the title of the Assignee, its successors and assigns, in and to said inventions and discoveries, and in and to any and all Letters Patent or reissues thereof which may be granted upon application in any and all countries in the world.

AND we hereby authorize and request any official whose duty it is to issue patents to issue each and every Letters Patent to be granted upon the aforesaid Application in any and all countries, and each and every reissue of said Letters Patent, to the Assignee, its successors and assigns, as the assignee of our entire right, title and interest therein, in accordance with this assignment.


THIS assignment made effective as of October 5, 2012.

SIGNED this 6<sup>th</sup> day of March, 2014

  
WITNESS

  
MARC MANSOUR

SIGNED this 6<sup>th</sup> day of March, 2014

  
WITNESS

  
LISA DIANA MACDONALD

SIGNED this 6<sup>th</sup> day of March 2014

  
WITNESS

  
GENEVIEVE MARY WEIR

SIGNED this 6 day of March, 2014.



WITNESS




LEELADHAR SAMMATUR

SIGNED this 6 day of March, 2014.



WITNESS



KENDALL SHARP